crotoxin (CB-24) / Celtic Biotech - LARVOL DELTA

Open Label Clinical Trial of Intravenous Crotoxin Part 3 (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Celtic Biotech Ltd | Trial completion date: Dec 2025 ➔ Nov 2027 | Trial primary completion date: Aug 2025 ➔ Oct 2027

Trial completion date • Trial primary completion date • Oncology

Intra-patient dose escalation of crotoxin in advanced cancer: Cohort 2 (ESMO 2025) - "This event was classified as a possible drug-related Serious Adverse Event, also associated with prior chemotherapy (nivolumab and cisplatin). Funding CELTIC BIOTECH. 38/39 Fitzwilliam Square East DUBLIN D02 FX50 CO DUBLIN."

Clinical • Metastases • Brain Cancer • Choroidal Melanomas • Endometrial Adenocarcinoma • Endometrial Cancer • Glioblastoma • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Ocular Melanoma • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma

Crotoxin induces cytotoxic effects in human malignant melanoma cells in both native and detoxified forms. (PubMed, Front Pharmacol) - "These results confirm the antitumoral potential of CTX. The maintenance of the antiproliferative effects in the detoxified version, with reduced enzymatic activity often liked to harm effects, supports further studies to identify active parts of the molecule responsible for the interesting effects without causing substantial toxic events, contributing to the future use of CTX-derived drugs with safety and efficacy."

Journal • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor • CASP3